Skip to content

Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery With Cardiopulmonary Bypass

Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery Using Conventional Blood Coagulation Tests or Thrombo-elastographic Point of Care Test - IMOTEC

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02972684
Acronym
IMOTEC
Enrollment
1098
Registered
2016-11-23
Start date
2017-01-03
Completion date
2020-02-29
Last updated
2020-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Coagulation Disorders, Blood Transfusion, Bypass, Cardiopulmonary, C.Surgical Procedure; Cardiac, Hemostatic

Keywords

Cardiopulmonary Bypass, Hemorrhage, blood transfusion, Point-of-care test, health economics

Brief summary

Peri operative haemorrhage following cardio Pulmonary Bypass may occur in 5 to 10% of cardiac surgical interventions. Treatment of such complication often necessitates various combinations therapeutic intervention including allogenic blood products administration, drug use and/or surgical intervention. All are expensive treatment and decision making is guided by patient clinical status and biological tests of the haemostatic function. A key point is the time frame of the clinical process. Therapeutic choices have to be done as fast as possible to minimize bleeding consequences on patient haemodynamic and physiological status. Conventional coagulation test results availability time usually exceed 45' after blood drawing. In such situation, the results may not reflect precisely the coagulation system current state. This downside is often counterbalanced by clinicians empirical choices preceding lab test results knowledge that may conduct to inappropriate treatment, blood product overuse and undue expense. Viscoelastic point of care test may compensate for the limitations of conventional coagulation tests. In perioperative haemorrhage, faster and more precise information about haemostatic function may help for more accurate therapeutic choices. The IMOTEC study aims to compare haemorrhage management following cardiac surgery using conventional blood coagulation tests or thrombo-elastogaphic point of care test. Primary endpoint is a cost utility analysis of the technology and secondary endpoints include blood component transfusion, postoperative bleeding , thoracic re-intervention, postoperative infection (any cause), organ failure, in hospital length of stay and death.

Detailed description

The research is a real life, prospective, single blinded stepped wedge randomized study. Inclusion after informed consent of adult patient having cardio-vascular surgical procedure using cardiopulmonary bypass and meeting inclusion criterion bleeding. After meeting inclusion criterion patients are managed either using conventional blood coagulation tests or using thrombo-elastometry POC test and predefined therapeutic interventions described in a specific algorithm. Other elements of patient clinical management follow usual center standard care . Follow up of EQ-5D and clinical evaluations are performed at one , 6 and 12 months after inclusion.

Interventions

DEVICEThrombo-elastometry POC testing

Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage

Sponsors

Ministry of Health, France
CollaboratorOTHER_GOV
Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Pre-Inclusion Criteria: * Adult patients over 18 years old scheduled for elective or urgent cardiac surgery using cardiopulmonary bypass . * Patient informed written consent (non-opposition to data use) or person of trust or family member information . Inclusion Criteria: Blood Coagulation test sampling indication for intra or post-operative bleeding defined as follow: 1. intra-operative post CPB bleeding; evaluation more than 10min after heparin reversal by protamin. * Clinically significant bleeding judged on surgeon and anesthesiologist consensual point of view * Sternal closure delay * Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h) 2. Postoperative period , evaluation in post operative care environment after 30min stabilization period * Chest tube bleeding exceeding 50ml in 10min or more than 1ml/kg in 30min (2ml/kg/h) * Patient requiring surgical re-exploration for diagnosed or suspected pericardial effusion or surgical site bleeding requiring surgical hemostatic intervention

Exclusion criteria

* Known congenital bleeding disorder * Redo surgery for patient previously included in the study * Implantation of Cardiac support device, Extra Corporeal Membrane Oxygenation (ECMO) Extra Corporeal Life support (ECLS), uni or bi-ventricular artificial hearts. * Indication for post-CPB ECMO or ECLS * blood transfusion refusal * pregnant women * patients under 18 years old * Adult patient under guardianship, trusteeship or safeguard justice

Design outcomes

Primary

MeasureTime frameDescription
Cost-utility ratioone yearincremental cost per incremental life year and incremental costs per incremental QALY

Secondary

MeasureTime frameDescription
incremental cost effectiveness ratioone yearincremental cost effectiveness ratio : difference in costs divided by the difference in mortality and serious adverse events
Complication ratesone yearParameters followed during hospitalization are: volume of postoperative bleeding, allogeneic blood product transfusion, blood cell count, postoperative complications: surgical reexploration, acute kidney injury, need for renal replacement therapy, organ failure, acquired infections, mechanical ventilation duration, intensive care, and in hospital length of stay, death.
Evaluation surveyDay 1Evaluation survey regarding the context and the parameters that impacted the physician's decision, which will be used a sub-group of 100 patients.
The location of the Thrombo-elastometry POC testingthree yearsThe location of the Thrombo-elastometry POC testing (operative room or laboratory)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026